Rafał Dziadziuszko

Research interests

Publications

• Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2302299

• Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2310532

• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2307980

• ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.02.003

• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.06.017

• Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.010

• Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.04.478

• Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

  Radiotherapy and Oncology · 2020 · https://doi.org/10.1016/j.radonc.2020.04.001

• Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.07.025

• Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30690-4

• Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy121

• Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1704795

• Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.58.3302

• Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1413654

• Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

  JNCI Journal of the National Cancer Institute · 2007 · https://doi.org/10.1093/jnci/djk195

• Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2006.06.3958

Current projects

No projects listed.